Hetero-oligomerization between the TNF receptor superfamily members CD40, Fas and TRAILR2 modulate CD40 signalling.
TNF receptor superfamily members (TNFRSF) such as CD40, Fas and TRAIL receptor 2 (TRAILR2) participate to the adaptive immune response by eliciting survival, proliferation, differentiation and/or cell death signals. The balance between these signals determines the fate of the immune response. It was previously reported that these receptors are able to self-assemble in the absence of ligand through their extracellular regions. However, the role of this oligomerization is not well understood, and none of the proposed hypotheses take into account potential hetero-association of receptors. Using CD40 as bait in a flow cytometry Förster resonance energy transfer assay, TNFRSF members with known functions in B cells were probed for interactions. Both Fas and TRAILR2 associated with CD40. Immunoprecipitation experiments confirmed the interaction of CD40 with Fas at the endogenous levels in a BJAB B-cell lymphoma cell line deficient for TRAILR2. TRAILR2-expressing BJAB cells displayed a robust CD40-TRAILR2 interaction at the expense of the CD40-Fas interaction. The same results were obtained by proximity ligation assay, using TRAILR2-positive and -negative BJAB cells and primary human B cells. Expression of the extracellular domains of Fas or TRAILR2 with a glycolipid membrane anchor specifically reduced the intrinsic signalling pathway of CD40 in 293T cells. Conversely, BJAB cells lacking endogenous Fas or TRAILR2 showed an increased NF-κB response to CD40L. Finally, upregulation of TRAILR2 in primary human B cells correlated with reduced NF-κB activation and reduced proliferation in response to CD40L. Altogether, these data reveal that selective interactions between different TNFRSF members may modulate ligand-induced responses upstream signalling events.
Institut de Biologie Moléculaire et Cellulaire UPR 3572 'Immunopathologie et Chimie Thérapeutique' du CNRS, 15 Rue René Descartes, Strasbourg Cedex 67084, France.|Department of Biochemistry, University of Lausanne, Ch. des Boveresses 155, Epalinges CH-1066, Switzerland.|Center for Chronic Immunodeficiency, University Medical Centre Freiburg and University of Freiburg, Engesserstrasse. 4, Freiburg D-79110, Germany.
Cristian R
CR
Smulski
Institut de Biologie Moléculaire et Cellulaire UPR 3572 'Immunopathologie et Chimie Thérapeutique' du CNRS, 15 Rue René Descartes, Strasbourg Cedex 67084, France.
Marion
M
Decossas
Institut de Biologie Moléculaire et Cellulaire UPR 3572 'Immunopathologie et Chimie Thérapeutique' du CNRS, 15 Rue René Descartes, Strasbourg Cedex 67084, France.
Neila
N
Chekkat
Institut de Biologie Moléculaire et Cellulaire UPR 3572 'Immunopathologie et Chimie Thérapeutique' du CNRS, 15 Rue René Descartes, Strasbourg Cedex 67084, France.
Julien
J
Beyrath
Department of Biochemistry, University of Lausanne, Ch. des Boveresses 155, Epalinges CH-1066, Switzerland.
Laure
L
Willen
Institut Européen de Chimie et Biologie CBMN UMR5248 - CNRS/UB1, 2 rue Robert Escarpit, Pessac Cedex F-33607, France.
Gilles
0000-0002-2584-7502
G
Guichard
Center for Chronic Immunodeficiency, University Medical Centre Freiburg and University of Freiburg, Engesserstrasse. 4, Freiburg D-79110, Germany.
Raquel
R
Lorenzetti
Center for Chronic Immunodeficiency, University Medical Centre Freiburg and University of Freiburg, Engesserstrasse. 4, Freiburg D-79110, Germany.|Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg, Freiburg, Germany.
Marta
M
Rizzi
Center for Chronic Immunodeficiency, University Medical Centre Freiburg and University of Freiburg, Engesserstrasse. 4, Freiburg D-79110, Germany.
Hermann
H
Eibel
Department of Biochemistry, University of Lausanne, Ch. des Boveresses 155, Epalinges CH-1066, Switzerland.
Pascal
0000-0003-0677-9409
P
Schneider
Institut de Biologie Moléculaire et Cellulaire UPR 3572 'Immunopathologie et Chimie Thérapeutique' du CNRS, 15 Rue René Descartes, Strasbourg Cedex 67084, France.
Sylvie
S
Fournel
D001402:B-Lymphocytes / Q000378:metabolism; D019013:CD40 Antigens / Q000378:metabolism*; D023201:CD40 Ligand / Q000378:metabolism; D002460:Cell Line; D005786:Gene Expression Regulation / Q000502:physiology; D057809:HEK293 Cells; D006801:Humans; D016328:NF-kappa B / Q000378:metabolism; D058105:Polymerization; D054730:Protein Interaction Domains and Motifs / Q000502:physiology; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand / Q000378:metabolism*; D018124:Receptors, Tumor Necrosis Factor / Q000378:metabolism*; D015398:Signal Transduction / Q000502:physiology; D014407:Tumor Cells, Cultured; D015854:Up-Regulation / Q000502:physiology; D019014:fas Receptor / Q000378:metabolism*
D019013:CD40 Antigens; D016328:NF-kappa B; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand; D018124:Receptors, Tumor Necrosis Factor; D019014:fas Receptor; D023201:CD40 Ligand